SCHOTT PHARMA AG & CO. KGAA SCHOTT Pharma AG & Co. KGaA Share Price
Equities
1SXP
DE000A3ENQ51
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.66 EUR | -0.97% |
|
-3.42% | +9.11% |
| 05-10 | SCHOTT PHARMA : Gets a Neutral rating from Barclays | ZD |
| 04-22 | SCHOTT PHARMA : Jefferies remains Neutral | ZD |
| Sales 2024 * | 981M 1.06B 84.42B | Sales 2025 * | 1.15B 1.24B 98.88B | Capitalization | 5.52B 5.95B 475B |
|---|---|---|---|---|---|
| Net income 2024 * | 151M 163M 12.99B | Net income 2025 * | 189M 204M 16.26B | EV / Sales 2024 * | 5.83 x |
| Net Debt 2024 * | 201M 216M 17.27B | Net Debt 2025 * | 184M 199M 15.88B | EV / Sales 2025 * | 4.97 x |
| P/E ratio 2024 * |
36.6
x | P/E ratio 2025 * |
29.3
x | Employees | 4,687 |
| Yield 2024 * |
0.43% | Yield 2025 * |
0.55% | Free-Float | 23% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.97% | ||
| 1 week | -3.42% | ||
| Current month | -6.77% | ||
| 1 month | -8.07% | ||
| 3 months | -6.48% | ||
| 6 months | +29.63% | ||
| Current year | +9.11% |
1 week
35.58
38.92
1 month
35.5840.48
Current year
30.6043.40
1 year
27.0043.40
3 years
27.0043.40
5 years
27.0043.40
10 years
27.0043.40
| Managers | Title | Age | Since |
|---|---|---|---|
Andreas Reisse
CEO | Chief Executive Officer | 63 | 30/06/22 |
| Director of Finance/CFO | 43 | 30/06/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eva Kienle
BRD | Director/Board Member | 57 | 31/12/22 |
Wolfgang Wienand
BRD | Director/Board Member | 52 | 31/12/22 |
| Chairman | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 36.66 | -0.97% | 75,745 |
| 09/05/24 | 37.02 | -4.34% | 65,965 |
| 08/05/24 | 38.7 | +2.76% | 38,666 |
| 07/05/24 | 37.66 | +1.40% | 48,360 |
| 06/05/24 | 37.14 | -2.16% | 27,319 |
Delayed Quote Xetra, May 10, 2024 at 04:35 pm
More quotes
SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The Company's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.
Calendar
26/06/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
36.66
EUR
Average target price
38.67
EUR
Spread / Average Target
+5.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.11% | 5.95B | |
| -4.84% | 182B | |
| +0.56% | 110B | |
| -3.35% | 68.11B | |
| +2.39% | 50.53B | |
| +9.36% | 44.8B | |
| +2.70% | 40.7B | |
| +3.43% | 26.53B | |
| +13.67% | 25.02B | |
| -0.32% | 24.96B |
- Stock Market
- Equities
- 1SXP Stock
